Author

Iris Dotan

A SIMPLE WEB-BASED TOOL FOR PREDICTING DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS USING EXPLAINABLE ARTIFICIAL INTELLIGENCE
A SIMPLE WEB-BASED TOOL FOR PREDICTING DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS USING EXPLAINABLE ARTIFICIAL INTELLIGENCE

Iris Dotan  et al.

REDUCED TREATMENT ESCALATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH DIABETES MELLITUS USING NEWER ANTI-DIABETIC MEDICATIONS: AN ANALYSIS FROM THE EPI-IIRN
REDUCED TREATMENT ESCALATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH DIABETES MELLITUS USING NEWER ANTI-DIABETIC MEDICATIONS: AN ANALYSIS FROM THE EPI-IIRN

Iris Dotan  et al.

CROHN'S DISEASE EXCLUSION DIET INDUCES REMISSION IN ADULTS WITH MILD TO MODERATE CROHN´S DISEASE: PRELIMINARY REPORT FROM A RANDOMISED CONTROLLED TRIAL (CDED-AD TRIAL)
CROHN'S DISEASE EXCLUSION DIET INDUCES REMISSION IN ADULTS WITH MILD TO MODERATE CROHN´S DISEASE: PRELIMINARY REPORT FROM A RANDOMISED CONTROLLED TRIAL (CDED-AD TRIAL)

Iris Dotan  et al.

A GLOBAL CONSENSUS ON THE DEFINITIONS, DIAGNOSIS AND MANAGEMENT OF FIBROSTENOSING SMALL BOWEL CROHN'S DISEASE
A GLOBAL CONSENSUS ON THE DEFINITIONS, DIAGNOSIS AND MANAGEMENT OF FIBROSTENOSING SMALL BOWEL CROHN'S DISEASE

Iris Dotan  et al.

MUCUS COMPOSITION ALTERATIONS IN INFLAMMATORY BOWEL DISEASES (IBD)
MUCUS COMPOSITION ALTERATIONS IN INFLAMMATORY BOWEL DISEASES (IBD)

Iris Dotan  et al.

MORTALITY IN ELDERLY-ONSET INFLAMMATORY BOWEL DISEASES – A POPULATION-BASED STUDY FROM THE EPIDEMIOLOGICAL DATABASE OF THE ISRAELI IBD RESEARCH NUCLEUS (EPI-IIRN)
MORTALITY IN ELDERLY-ONSET INFLAMMATORY BOWEL DISEASES – A POPULATION-BASED STUDY FROM THE EPIDEMIOLOGICAL DATABASE OF THE ISRAELI IBD RESEARCH NUCLEUS (EPI-IIRN)

Iris Dotan  et al.

REAL-WORLD EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A POOLED MULTICENTRE OBSERVATIONAL COHORT ANALYSIS OF CLINICAL AND MODELED PHARMACOLOGICAL DATA
REAL-WORLD EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A POOLED MULTICENTRE OBSERVATIONAL COHORT ANALYSIS OF CLINICAL AND MODELED PHARMACOLOGICAL DATA

Iris Dotan  et al.

ASSOCIATION OF ANTIBIOTIC USE WITH DURABILITY OF BIOLOGIC AGENTS IN INFLAMMATORY BOWEL DISEASE: A REPORT FROM THE EPI-IIRN
ASSOCIATION OF ANTIBIOTIC USE WITH DURABILITY OF BIOLOGIC AGENTS IN INFLAMMATORY BOWEL DISEASE: A REPORT FROM THE EPI-IIRN

Iris Dotan  et al.

HUMAN INTESTINAL EPITHELIAL CELLS INTERNALIZE LUMINAL FUNGI VIA LC3-ASSOCIATED PHAGOCYTOSIS
HUMAN INTESTINAL EPITHELIAL CELLS INTERNALIZE LUMINAL FUNGI VIA LC3-ASSOCIATED PHAGOCYTOSIS

Iris Dotan  et al.

RISK FACTORS AND EFFICACY OF BIOLOGIC THERAPY FOLLOWING ILEAL POUCH-ANAL ANASTOMOSIS AMONG PATIENTS WITH ULCERATIVE COLITIS: LONG-TERM DATA FROM A PROSPECTIVE COHORT
RISK FACTORS AND EFFICACY OF BIOLOGIC THERAPY FOLLOWING ILEAL POUCH-ANAL ANASTOMOSIS AMONG PATIENTS WITH ULCERATIVE COLITIS: LONG-TERM DATA FROM A PROSPECTIVE COHORT

Iris Dotan  et al.

PRELIMINARY RESULTS OF A NOVEL COMPUTER AIDED DETECTION SYSTEM FOR PANCREATIC LESIONS ON EUS
PRELIMINARY RESULTS OF A NOVEL COMPUTER AIDED DETECTION SYSTEM FOR PANCREATIC LESIONS ON EUS

Iris Dotan  et al.

A MEDITERRANEAN DIET-BASED NUTRITIONAL EDUCATION PROGRAM POSITIVELY MODIFIES THE INTESTINAL MICROENVIRONMENT OF HEALTHY INDIVIDUALS: RESULTS FROM A PROSPECTIVE INTERVENTION
A MEDITERRANEAN DIET-BASED NUTRITIONAL EDUCATION PROGRAM POSITIVELY MODIFIES THE INTESTINAL MICROENVIRONMENT OF HEALTHY INDIVIDUALS: RESULTS FROM A PROSPECTIVE INTERVENTION

Iris Dotan  et al.

THE ASSOCIATION OF INFLAMMATORY BOWEL DISEASE WITH CELIAC DISEASE AND CELIAC AUTOIMMUNITY, IN CHILDREN AND ADULTS: A NATIONWIDE STUDY FROM THE EPI-IIRN
THE ASSOCIATION OF INFLAMMATORY BOWEL DISEASE WITH CELIAC DISEASE AND CELIAC AUTOIMMUNITY, IN CHILDREN AND ADULTS: A NATIONWIDE STUDY FROM THE EPI-IIRN

Iris Dotan  et al.

EXTERNAL VALIDATION OF A NOVEL EXPLAINABLE AI-DERIVED WEB TOOL FOR PREDICTING DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS
EXTERNAL VALIDATION OF A NOVEL EXPLAINABLE AI-DERIVED WEB TOOL FOR PREDICTING DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS

Iris Dotan  et al.

QINGDAI (QD) FOR PATIENTS WITH ACTIVE ULCERATIVE COLITIS: A RETROSPECTIVE ISRAELI NATIONAL EXPERIENCE
QINGDAI (QD) FOR PATIENTS WITH ACTIVE ULCERATIVE COLITIS: A RETROSPECTIVE ISRAELI NATIONAL EXPERIENCE

Iris Dotan  et al.

FAVOURABLE FIRST YEAR REMISSION RATES AMONG PATIENTS WITH NEWLY DIAGNOSED CROHN'S DISEASE: DATA FROM A REAL-WORLD PROSPECTIVE INCEPTION COHORT
FAVOURABLE FIRST YEAR REMISSION RATES AMONG PATIENTS WITH NEWLY DIAGNOSED CROHN'S DISEASE: DATA FROM A REAL-WORLD PROSPECTIVE INCEPTION COHORT

Iris Dotan  et al.

MICROBIAL SIGNATURE OF PATIENTS WITH NEWLY DIAGNOSED CROHN’S DISEASE IDENTIFIES PATIENTS WITH COMPLICATED DISEASE COURSE
MICROBIAL SIGNATURE OF PATIENTS WITH NEWLY DIAGNOSED CROHN’S DISEASE IDENTIFIES PATIENTS WITH COMPLICATED DISEASE COURSE

Iris Dotan  et al.

DECREASED IMMUNE RESPONSE TO COVID-19 MRNA VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI TNF?: A PROSPECTIVE, CONTROLLED, MULTI-CENTER ISRAELI STUDY
DECREASED IMMUNE RESPONSE TO COVID-19 MRNA VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI TNF?: A PROSPECTIVE, CONTROLLED, MULTI-CENTER ISRAELI STUDY

Iris Dotan  et al.

SEROLOGIC RESPONSE AND SAFETY AFTER THIRD DOSE OF THE COVID-19 BNT162B2 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
SEROLOGIC RESPONSE AND SAFETY AFTER THIRD DOSE OF THE COVID-19 BNT162B2 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Iris Dotan  et al.

Item 21 - 39 / 39
1
2